Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Cash from Operations (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Cash from Operations for 7 consecutive years, with 83289000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations fell 9.07% to 83289000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 345102000.0, a 0.62% increase, with the full-year FY2025 number at 345102000.0, up 0.62% from a year prior.
  • Cash from Operations was 83289000.0 for Q4 2025 at Beam Therapeutics, down from 81479000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 218490000.0 in Q1 2022 to a low of 109815000.0 in Q1 2023.
  • A 5-year average of 44264200.0 and a median of 76407500.0 in 2024 define the central range for Cash from Operations.
  • Biggest YoY gain for Cash from Operations was 666.36% in 2022; the steepest drop was 3880.93% in 2022.
  • Beam Therapeutics' Cash from Operations stood at 1830000.0 in 2021, then plummeted by 3880.93% to 69191000.0 in 2022, then skyrocketed by 295.22% to 135073000.0 in 2023, then tumbled by 156.54% to 76365000.0 in 2024, then dropped by 9.07% to 83289000.0 in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Cash from Operations are 83289000.0 (Q4 2025), 81479000.0 (Q3 2025), and 76450000.0 (Q2 2025).